ISRG·Healthcare·Pharma
Intuitive Surgical Earnings: Stock Surges 2.6% Ahead of Q2 Release
Will the highly anticipated Intuitive Surgical Earnings release justify the stock's premium valuation and spark a sustainable Wall Street rally?
Pharma
ISRG·Healthcare·Pharma
JNJ·Healthcare·Dividend Aristocrats
Johnson & Johnson Earnings: $21 Billion Swing Ahead of Key Print
Can the upcoming Johnson & Johnson Earnings report justify the healthcare giant's premium valuation after a massive defensive stock rally?
BMY·Healthcare·Pharma
Bristol Myers Squibb Pricing Under Pressure: Stock Drops 2%
Will the combination of new global price caps and looming patent cliffs permanently derail Bristol Myers Squibb's long-term growth story?
LLY·Healthcare·Pharma
Eli Lilly Weight Loss Stock Drops 2.6% on Slow Foundayo Launch
Can Eli Lilly's superior weight-loss efficacy overcome a surprisingly slow start for its highly anticipated oral drug Foundayo?
NVO·Healthcare·Pharma
Novo Nordisk Study Data: Hemophilia Breakthroughs and Pipeline Updates
Will Novo Nordisk's impressive new hemophilia data be enough to offset Eli Lilly's aggressive market share gains in the obesity…
AZN·Healthcare·Pharma
AstraZeneca Wainua Trial -8.8% After Phase III Miss
Can AstraZeneca contain the damage after the AstraZeneca Wainua Trial miss erased billions in market value in a single session?
LLY·Healthcare·Pharma
Eli Lilly Medicare Obesity: $15B Market Boom Builds
Can Medicare coverage and faster FDA plant approvals turn Eli Lilly’s obesity franchise into an even bigger profit machine?
LLY·Healthcare·Pharma
Eli Lilly Record at $1 Trillion as GLP-1 Boom Lifts LLY
Can Eli Lilly’s record run keep defying gravity as GLP-1 dominance and billion-dollar dealmaking reshape Big Pharma?
LLY·Healthcare·Pharma
Eli Lilly Jaypirca Approval +6.8% as CHMP Backs CLL Use
Can Eli Lilly Jaypirca Approval turn a regulatory win into a lasting oncology growth engine for investors?
PFE·Healthcare·Pharma
Pfizer Lung Cancer Trial Sends Warning on Oncology Pivot
Can Pfizer’s lung cancer setback stay contained to one trial, or is it an early warning for its broader oncology…